GeoVax Labs, Inc. is conducting a study to evaluate a self-administered GEO-MVA vaccine using Vaxxas Microarray Patch Technology, aiming to create a needle-free, thermostable vaccine for pandemic preparedness. Meanwhile, Lexaria Bioscience Corp. has reported positive interim results on their DehydraTECH-semaglutide, showing a reduction in side effects compared to Rybelsus®, demonstrating patient safety and tolerability.
